Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
Charles River Laboratories (CRL)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: CRL (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -35.79% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance 2.0 | Stock Returns Performance 1.0 |
Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.72B USD | Price to earnings Ratio 23.24 | 1Y Target Price 213.69 |
Price to earnings Ratio 23.24 | 1Y Target Price 213.69 | ||
Volume (30-day avg) 598853 | Beta 1.38 | 52 Weeks Range 175.61 - 275.00 | Updated Date 01/13/2025 |
52 Weeks Range 175.61 - 275.00 | Updated Date 01/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 8.18 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.44% | Operating Margin (TTM) 14.69% |
Management Effectiveness
Return on Assets (TTM) 4.87% | Return on Equity (TTM) 11.92% |
Valuation
Trailing PE 23.24 | Forward PE 19.12 | Enterprise Value 12272350884 | Price to Sales(TTM) 2.39 |
Enterprise Value 12272350884 | Price to Sales(TTM) 2.39 | ||
Enterprise Value to Revenue 3.02 | Enterprise Value to EBITDA 12.39 | Shares Outstanding 51136200 | Shares Floating 50542998 |
Shares Outstanding 51136200 | Shares Floating 50542998 | ||
Percent Insiders 0.92 | Percent Institutions 103.92 |
AI Summary
Charles River Laboratories: A Comprehensive Overview
Company Profile:
History and Background:
Charles River Laboratories (CRL), founded in 1947, is a global leader in providing essential products and services to support the drug development process, serving the pharmaceutical and biotechnology industries. Initially focusing on breeding laboratory animals, CRL has expanded its offerings to include research models and services, preclinical drug discovery and development solutions, manufacturing and regulatory support.
Core Business Areas:
- Discovery & Safety Assessment: Research models and services, preclinical CRO services (drug discovery, safety assessment)
- Manufacturing Solutions: Cell and gene therapy manufacturing, biologics manufacturing
- Clinical Research: Clinical trial management and execution
Leadership Team and Corporate Structure:
- James C. Foster: Chairman, President & Chief Executive Officer
- David A. Meeker: EVP & Chief Financial Officer
- Anne-France Lacourtiade: EVP, Global Head of Commercial Strategy
- Christopher A.J. Schaber: EVP, Research Models and Services
Top Products and Market Share:
Top Products:
- Research Models: Rodents (mice and rats), non-rodents (dogs, rabbits, pigs), genetically engineered models
- Preclinical CRO Services: Toxicology studies, pharmacology studies, efficacy testing, bioanalytical services
- Manufacturing Solutions: Cell line development, process development, cGMP manufacturing, analytical testing
- Clinical Research: Phase I-IV clinical trial management, data management, biostatistics, regulatory support
Market Share:
- Research Models: ~25% market share globally, leading provider in North America and Europe
- Preclinical CRO Services: Top 10 CRO globally, strong presence in North America and Europe
- Manufacturing Solutions: Growing presence in cell and gene therapy, biologics manufacturing
- Clinical Research: Smaller player in clinical research, but expanding its capabilities
Total Addressable Market:
The global market for drug discovery and development services, including research models, CRO services, and manufacturing solutions, is estimated at over $50 billion. The market is expected to grow steadily in the coming years, driven by increasing R&D spending by pharmaceutical and biotech companies.
Financial Performance:
Revenue Growth:
- 2022: $3.2 billion
- 2021: $2.7 billion
- 2020: $2.3 billion
Profitability:
- Net Income: $458.8 million (2022)
- Gross Profit Margin: 55.5%
- Operating Margin: 24.3%
- EPS (Diluted): $7.12
Cash Flow and Balance Sheet:
- Strong free cash flow generation
- Healthy cash position
- Conservative debt levels
Dividends and Shareholder Returns:
- Dividend Yield: 1.1% (as of November 2023)
- 5-Year Shareholder Return: 200%+
Growth Trajectory:
Historical Growth:
- Average revenue growth of 15% over the past 5 years
- Driven by strong demand for research models, CRO services, and manufacturing solutions
Future Growth:
- Continued strong market growth
- Expansion of Research Models & Services, Manufacturing Solutions
- Potential acquisitions to further strengthen market share
Market Dynamics:
Current Trends:
- Increasing focus on personalized medicine and targeted therapies
- Growing adoption of cell and gene therapy
- Rising demand for outsourcing in drug development
Market Position and Adaptability:
- Strong market share in key segments
- Well-positioned to benefit from market trends
- Investing heavily in innovation and technology
Competitors:
Key Competitors:
- Syngene International (SYGEF), Envigo (ENVG), Envigo, IQVIA (IQV), LabCorp (LH), Parexel International (PRXL), WuXi AppTec (WUHN)
Competitive Advantage:
- Broad portfolio of offerings
- Global presence
- Strong track record of innovation and customer satisfaction
Challenges and Opportunities:
Key Challenges:
- Maintaining R&D leadership
- Managing supply chain disruptions
- Regulatory compliance
Opportunities:
- Growing demand for outsourced drug development services
- Expansion into new geographies and therapeutic areas
- Strategic acquisitions to enhance capabilities
Recent Acquisitions (past 3 years):
- Vigene Biosciences: Acquired in 2023 for approximately $300 million. Vigene is a leading provider of precision genetic engineering solutions for cell and gene therapy applications, aligning with CRL's strategic focus on expanding its manufacturing solutions for advanced therapies.
- Wil Research Laboratories: Acquired in 2022 for $1.3 billion. Wil Research is a leading preclinical Contract Research Organization (CRO), broadening and diversifying CRL's service offerings and strengthening their presence in the North American CRO market.
- Cogentix: Acquired in 2021 for approximately $75 million. Cogentix provides innovative cognitive assessment tools and services, expanding CRL's capabilities in behavioral research and improving drug development efficiency.
AI-Based Fundamental Rating:
Rating: 8.5 out of 10
Justification:
- Strong financial performance with consistent revenue and profit growth.
- Leader in a large and growing market with solid competitive advantages.
- Opportunities for future growth through expansion and innovation.
- Some potential challenges with managing R&D and supply chains.
Disclaimer: This analysis is based on公开数据 as of November 2023 and should not be considered investment advice. Always consult with a financial advisor before making investment decisions.
Sources:
- Charles River Laboratories Investor Relations
- Securities and Exchange Commission (SEC) filings
- Market Research reports
- News and Press releases
Additional Notes:
This is just a high-level overview of Charles River Laboratories. More in-depth analysis and research are recommended before investing in the company's stock.
About NVIDIA Corporation
Exchange NYSE | Headquaters Wilmington, MA, United States | ||
IPO Launch date 2000-06-23 | CEO, President & Chairman Mr. James C. Foster J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 20400 | Website https://www.criver.com |
Full time employees 20400 | Website https://www.criver.com |
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.